Oral iron supplementation in patients with heart failure: a systematic review and meta-analysis

Zhiping Song†, Mingyang Tang‡, Gang Tang*, Guoqi Fu*, Dengke Ou*, Fengyou Yao*, Xingzhi Hou†* and Denghong Zhang‡*

*Department of Cardiovascular Medicine, Yuechi County People’s Hospital, Guang’an, China; †Geriatric Diseases Institute of Chengdu / Cancer Prevention and Treatment Institute of Chengdu, Department of Cardiology, Chengdu Fifth People’s Hospital (The Second Clinical Medical College, Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China

Abstract

Aims This review aimed to assess whether oral iron supplementation in a chronic heart failure (HF) population with iron deficiency (ID) or mild anaemia is safe and effective according to evidence-based medicine.

Methods We retrieved 1803 records from the PubMed, Embase, and the Cochrane Library databases from 1 January 1991 to 15 September 2021. The clinical outcome of oral iron supplementation for ID anaemia in patients with HF was the primary endpoint. The primary safety measures included adverse events and all-cause mortality, and efficacy measures included transferrin saturation (Tsat), ferritin levels, and the 6-min walk test (6MWT). The rate ratio (RR) was used to pool the efficacy measures.

Results Five randomized controlled trials that compared oral iron treatment for patients with the placebo group and included a combined total of 590 participants were analysed. No significant difference was found in all-cause death between oral iron treatment and placebo groups (RR = 0.77; 95% confidence intervals (CI), 0.46–1.29, Z = 0.98; P = 0.33). However, adverse events were not significantly higher in the iron treatment group (RR = 0.83; 95% CI, 0.60–1.16, Z = 1.07; P = 0.28). In addition, ferritin levels and Tsat were slightly increased after iron complex administration in patients with HF but were not statistically significant (ferritin: mean difference [MD] = 4.93 to 59.78, Z = 1.51; P = 0.13). We also analysed two non-randomized controlled trials with follow-up results showing that oral iron supplementation increased serum iron levels (MD = 28.87, 95% CI, 1.62–56.12, Z = 2.08; P = 0.04).

Conclusions Based on the current findings, oral iron supplementation can increase serum iron levels in patients with HF and ID or mild anaemia but does not improve Tsat and 6MWT. In addition, oral iron supplementation is relatively safe.

Keywords Heart failure; Oral iron; Iron deficiency; Anaemia; Efficacy; Safety

Received: 16 November 2021; Revised: 19 March 2022; Accepted: 3 June 2022

Introduction

Heart failure (HF) is a chronic disabling syndrome associated with a lower quality of life and shorter longevity, which could be described as a ‘malignant condition’ owing to its poor prognosis1,2 and a 10% prevalence in people aged ≥65 years,3,4 resulting in high mortality and a huge social burden.5 Approximately 30–50% of stable patients with HF have iron deficiency (ID) or anaemia during the remainder of life,6 which is an independent risk factor for patients with HF. ID can further reduce functional capacity, impair the quality of life, and ultimately increase the re-hospitalization rate and economic costs.7–9 Therefore, the impact of iron treatment on patients with HF and ID or anaemia would be of clinical interest.
Iron supplementation is a better option for patients with HF and anaemia. Recent randomized controlled trials (RCTs) and meta-analyses have shown that intravenous iron administration contributes to increased iron bioavailability and exercise capacity, as well as decreased re-hospitalization.\textsuperscript{10–13} However, intravenous iron is relatively expensive and inconvenient to administer at scale for non-hospitalized patients, particularly in many countries with limited healthcare resources.\textsuperscript{14–16} Furthermore, the safety of intravenous iron is unclear. In contrast, oral iron supplementation is easily available and more economic. Thus, clinicians often recommend oral iron. The disadvantages of intravenous iron place oral iron as a good alternative therapeutic approach. Nevertheless, absorption problems with oral administration have impeded its widespread use.

The safety of oral iron remains to be established, as gastrointestinal side effects have been reported. Meanwhile, several clinical studies have inconsistent results about oral administration.\textsuperscript{14,17–19} Partial clinical studies demonstrate that oral iron therapy can elevate haematological parameters and improve functional capacity,\textsuperscript{14,19,20} whereas recent studies report that it is ineffective in improving cardiac function.\textsuperscript{21} Two multicentre, double-blinded RCTs, IRON-HF and IRONOUT, have demonstrated that oral iron supplementation failed to raise the peak volume of oxygen consumption (VO\textsubscript{2}) and the distance in the 6-min walk test (6MWT) compared with placebo, which suggests against oral iron supplementation in patients with HF with ID or mild anaemia.\textsuperscript{16,17} Hence, we conducted a meta-analysis to establish the safety and efficacy of oral iron supplementation in the chronic HF population with ID or mild anaemia safe and effective.

**Methods**

**Data sources and search strategy**

A literature search was conducted on the Cochrane Library, PubMed, and Embase databases. The Medical Subject Headings keywords and free words used for the search were ‘anaemia’ and ‘heart failure’. Two researchers independently performed the search. When disparities occurred, consensus was reached through discussion and consultation. A flow chart of the literature search is shown in Figure 1.

**Inclusion and exclusion criteria**

Using the PICO model,\textsuperscript{22} the potential clinical trials that met the following criteria were considered for inclusion in the...
meta-analysis: (i) all symptomatic stages of HF [New York Heart Association (NYHA) Classes II–IV, with ejection fraction (LVEF) < 50%] with ID or anaemia (≥18 years old), (ii) oral iron administration to patients with HF, (iii) oral placebo or blank for control group, and (iv) evaluation of efficacy and safety of oral iron supplementation. The exclusion criteria were as follows: (i) studies on other diseases like chronic kidney disease, (ii) intravenous iron intervention or erythropoietin (EPO) combination treatment, and (iii) other research types, for example, retrospective study, review, systematic review, and meta-analysis.

Data extraction

The following data were independently extracted by two cardiologists: (i) population characteristics, including the number of participants, age, and sex; (ii) drug types, dosage, treatment duration, and the duration of follow-up; and (iii) the evaluation of results. When discrepancies occurred between the two cardiologists and could not be resolved, statistics experts were consulted or the original authors were sought for intervention by e-mail. In the process, a third reviewer supervised the work and censored the data to minimize mistakes and missing crucial information as much as possible.

Quality assessment

The risk of bias in this meta-analysis was assessed using the Cochrane Collaboration’s tool. Based on the standards specified in the manual, we graded each part as low risk for bias, unclear risk if lacking information or uncertain over the potential for bias, and high risk for bias. Furthermore, we assessed trials for methodological quality and examined bias for the following: selection bias, random sequence generation and allocation concealment; performance bias, blinding of participants and researchers; and attrition bias, incomplete outcome data, and other biases.

Statistical analysis

Data analysis was performed using Review Manager Version 5.3 software. The continuous variables, namely, ferritin level, transferrin saturation (Tsat), and 6MWT distance, were analysed by calculating the mean difference (MD) with standard deviation (SD) of the mean. When the sample mean and SD could not be directly obtained, other statistical methods were applied to estimate the approximate effect sizes. Dichotomous data were analysed using the rate ratio (RR), and each result was expressed with 95% confidence interval. Statistical heterogeneity was quantified via the $I^2$ statistic. An $I^2 > 50\%$ or $P < 0.1$ indicated significant heterogeneity. We used the random-effects model; otherwise, the fixed-effects model was applied. Sensitivity analysis was performed to estimate the statistical effect value with the addition of two studies. $P < 0.05$ was considered statistically significant.

Results

Article selection process

The article selection process is presented in Figure 1. A total of 1803 records were retrieved by electronic database search. After removing duplicates, 1417 records were included. After skimming the titles and abstracts, we removed 1364 studies that were irrelevant to our research topic. Subsequently, 59 potentially eligible studies were identified and recaptured for full-text scanning, but 54 articles did not match the inclusion criteria. Ultimately, five RCTs on oral iron administration to patients with HF with ID or mild anaemia were included in the meta-analysis.

Patient baseline characteristics

The baseline characteristics are summarized in Table 1. A total of 590 participants were included, with the age ranging from 18 to 75 years and the duration of follow-up ranging from 8 to 26 weeks. All patients underwent standard HF therapy, with the treatment group placed under oral iron therapy, whereas the control group was given placebo or blank. Ferrous sulfate and polysaccharide iron complex were administered with the dose varying from 150 to 350 mg. All patients had established chronic HF with LVEF < 50% and NYHA Classes II–IV. ID or mild anaemia was diagnosed based on a haemoglobin level of 8–15 g/dL, ferritin <100 ng/mL or between 100 and 300 mg/L, and Tsat <20%.

Risk of bias assessment

We expressed the quality of each risk of bias item presented as percentages based on the Cochrane risk of bias assessment manuals. Briefly, the five studies underwent random sequence generation. Only one trial had reported adequate allocation. Furthermore, one trial did not use blinding, whereas two trials were double-blinded, one of which had merely completed a blinded assessment of the outcomes. In addition, two trials had incomplete outcome data, and selective reporting was identified. No other significant biases were noted during quality assessment (Figure 2).
Table 1. The baseline characteristics of the studies included are presented

| Study                        | Area                  | Age (y) | Female, total | Age (y) | Female, total | Follow-up (w) | Drug, dosage | Results evaluation | Iron deficiency and anaemia (ferritin; Tsat; Hb) | Adverse effects on oral iron supplementation |
|------------------------------|-----------------------|---------|---------------|---------|---------------|----------------|--------------|------------------|-------------------------------------------------|------------------------------------------------|
| Beck-da-Silva 2013           | Porto Alegre, Brazil  | 4/13    | 63.5 ± 16.2   | 8       | 200 mg tid    | 8              | Ferrous sulfate; 200 mg tid | <500 μg/L (Tsat < 20%; Hb < 12 g/dL) | No significant increase in gastrointestinal adverse effects (RR = 0.83; 95% CI, 0.60–1.16, Z = 1.07; P = 0.28) (Figure 3B). |
| Suryani 2017                 | Jakarta, Indonesia    | NA      | NA            | NA      | 100 mg bid    | 12             | Ferrous sulfate; LVEF < 50%; proBNP | <100 μg/L (Tsat < 20%; Hb: 8–13 g/dL) | No significant difference in adverse effects (RR = 0.97; 95% CI, 0.77–1.23, Z = 0.63; P = 0.52) (Figure 4A). |
| Lewis 2017                   | Massachusetts, USA    | 80/225  | 63 (median)   | NA      | 150 mg tid    | 12             | Iron polysaccharide; sTfR; NT-proBNP | <100 μg/L (Tsat: VO2, VO2, 6MWT) | No significant difference in adverse effects (RR = 0.97; 95% CI, 0.77–1.23, Z = 0.63; P = 0.52) (Figure 4A). |
| Sagiota 2017                 | Jakarta, Indonesia    | NA      | NA            | NA      | 300 mg bid    | 26             | Ferrous fumarate; NT-proBNP | <100 mg/L (Tsat < 20%; Hb: 13 g/dL) | No significant increase in gastrointestinal adverse effects (RR = 0.83; 95% CI, 0.60–1.16, Z = 1.07; P = 0.28) (Figure 3B). |
| Snezana 2019                 | Nis, Serbia           | 79201   | 73.1 ± 7.66   | NA      | 350 mg bid    | 26             | Ferrous fumarate; NT-proBNP | <100 mg/L (Tsat: NT-proBNP) | No significant difference in adverse effects (RR = 0.97; 95% CI, 0.77–1.23, Z = 0.63; P = 0.52) (Figure 4A). |

Iron storage status and cardiac function

We assessed whether haematological parameters were improved remarkably after oral iron supplementation. The ferritin levels and Tsat were pooled and showed a slight increase after iron complex administration (ferritin: MD = 2.70, 95% CI, −2.41–7.81, Z = 1.04; P = 0.30; Tsat: MD = 27.42, 95% CI, −8.81–59.78, Z = 1.66; P = 0.10) (Figure 4A and 4B), but neither showed significant differences. The 6MWT, which was assessed in two trials, showed statistically significant heterogeneity (I^2 = 92%, P < 0.00001). After summarizing the results using the random-effects model, no significant difference was found (MD = 59.60, 95% CI, −17.89–137.08, Z = 1.51; P = 0.13) (Figure 4C).

Sensitivity analysis

In addition to the clinical trials, we included two well-designed, non-random control trials for sensitivity analysis to increase statistical samples and acquire more reliable results. Two articles described statistics on gastrointestinal adverse effects, and the heterogeneity from them diverged (I^2 = 79%, P = 0.03). Eleven (23.4%) candidates in the experimental group had gastrointestinal side effects, whereas the incidence in the control group is 18.4% (nine candidates). Synthesis analysis indicated that the oral iron administration group did not show a significant increase in gastrointestinal adverse effects. After adding the two studies, no changes were found in 6MWT and all adverse events. However, significant changes in ferritin levels were observed (I^2 = 88%, P < 0.0001) (MD = 28.87, 95% CI 1.62–56.12, Z = 2.08; P = 0.04) (Figure 5).
Discussion

Main findings

Our meta-analysis included studies comparing oral iron treatment with placebo or blank treatment in populations with HF with ID or mild anaemia. Our results reveal that oral iron is ineffective in improving the quality of life and exercise capacity of patients with HF with ID or mild anaemia. However, oral iron supplementation can improve iron storage status. More importantly, our findings indicate that oral iron therapy had no impact on adverse effects and all-cause death.

This study is the first to examine the safety and efficacy of oral iron in patients with HF with ID anaemia. The gastrointestinal canal of patients with HF is more susceptible to injury, and iron itself may have a negative effect on the gastrointestinal tract.27 However, compared with the control arm, no increase in adverse events was observed after oral iron intervention in the experimental group. Hence, the results indicate that oral iron supplementation is sufficiently harmless to patients with HF and can be considered safe for use.

Iron, as the essential component of haemoglobin and the mitochondrial electron transport chain complex, plays an indispensable role in the oxygen-carrying function and electron transport for ATP generation of the blood.28,29
Current experimental evidence indicates that appropriate iron supplementation can ameliorate muscle function and exercise capacity in animals, suggesting the function of iron as a co-factor in skeletal and cardiac muscles. The results of the analysis reveal that ferritin levels and Tsat showed a slight but non-significant increase. Therefore, oral iron treatment has a negligible effect on complementing iron stores, which can help improve aerobic exercise and increase high quality of life. However, the sensitivity analysis showed that oral iron significantly improved patients’ ferritin levels. Recent studies have reported that oral iron is effective in treating ID symptoms in patients with HF compared with intravenous iron supplementation. In the studies analysed, oral iron supplementation was administered at 200–600 mg per day, which is 10–20-fold the absorption capacity for oral iron after accounting for limited gastrointestinal tract intake. More surprisingly, the 6MWT and the Kansas City Cardiomyopathy Questionnaire (KCCQ) are unchanged after oral iron administration. To expand the sample size, we included two non-randomized controlled studies for sensitivity analysis, and the findings were the same. In consequence, the evidence reveals that the application of oral iron fails to alleviate clinical symptoms, increase exercise capacity, and improve quality of life in HF with ID or mild anaemia. Apart from that, indicators of cardiac structure and systolic function were not ameliorated after oral iron administration, for example. In addition, clinical trials have confirmed that ID may damage O₂ transport and utilization and decrease peak O₂ consumption, eventually leading to exercise intolerance and cardiac function decline in patients with HF. These situations were reversed with intravenous iron therapy. However, this is inconsistent with our current findings indicating no significant difference in peak O₂ consumption, which is a strong predictive factor of exercise capacity in the HF population. Furthermore, the 6MWT and the Kansas City Cardiomyopathy Questionnaire (KCCQ) are unchanged after oral iron administration. To expand the sample size, we included two non-randomized controlled studies for sensitivity analysis, and the findings were the same. In consequence, the evidence reveals that the application of oral iron fails to alleviate clinical symptoms, increase exercise capacity, and improve quality of life in HF with ID or mild anaemia. Apart from that, indicators of cardiac structure and systolic function were not ameliorated after oral iron administration, for example. In the studies analysed, oral iron supplementation was administered at 200–600 mg per day, which is 10–20-fold the absorption capacity for oral iron after accounting for limited gastrointestinal tract intake. More surprisingly, the total oral iron dosage in the IRON-HF trial was approximately 38-fold that for intravenous iron. Nevertheless, the efficacy of oral iron supplementation on iron storage status lags far behind intra-

Figure 4 Forest plot displaying (A) the Tsat and (B) the ferritin level after oral iron supplementation. (C) The 6MWT in HF patients with ID or anaemia.

Figure 5 Forest plot showing the sensitivity analysis on the ferritin level at the end of follow-up.
venous iron. According to the failure of oral iron to promote exercise function and iron storage status, several possible reasons may contribute to the phenomenon. As previously stated, gastrointestinal tract digestive and absorptive functions are impaired in the HF population, and massive oral iron can aggravate the injury, leading to excessive iron loss. Hepcidin is a crucial factor regulating iron absorption, and increased hepcidin levels will inhibit iron absorption and utilization. The IRONOUT trial showed very high baseline levels of hepcidin, which may suppress the Tsat and ferritin increase after oral iron supplementation, thereby restricting iron uptake in the skeletal muscle and cardiomyocytes. In addition, a follow-up duration of 2–4 months is short, which may have limited our evaluation.

Limitations

Our meta-analysis has some limitations. First, only a small number of studies were included, and high-quality trials are lacking. In addition, we were unable to gather more information for the assessment of prognosis as expected, for example, LVEF, re-hospitalization and long-term mortality. In addition, the definition of mild anaemia and ID is one of the limitations varied across the studies, and no standard recommendations exist on target Tsat, ferritin, and haemoglobin levels. Furthermore, we were unable to conduct sub-group analyses on anaemia status and NYHA class due to the limited data.

Conclusions

Our findings show that oral iron supplementation can safely improve iron storage status. However, oral iron supplementation in the HF population with ID or mild anaemia is ineffective in improving Tsat and 6MWT. The clinical trials on oral iron administration in HF with ID or anaemia are still very few. Therefore, further well-designed RCTs involving multiple centres and nationalities are still required. Furthermore, as our findings indicate, we recommend that ongoing and future trials should have long-term follow-up and should examine anaemic status, ID levels (based on ferritin and Tsat), NYHA class, and LVEF.

Acknowledgements

Our sincere gratitude to all.

Conflict of interest

None declared.

Funding

This study was not supported by specific funding.

References

1. Chang G, Zhang W, Zhang M, Ding G. Clinical value of circulating ZFAS1 and miR-590-3p in the diagnosis and prognosis of chronic heart failure. Cardiovasc Toxicol 2021; 21: 880–888.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007–2018.
3. Christiansen MN, Køber L, Weeke P, Vasan RS, Jeppesen JL, Smith JG, Gislason GH, Torp-Pedersen C, Andersson C. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation 2017; 135: 1214–1223.
4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137–1146.
5. Shi Y, Zhang L, Li W, Wang Q, Tian A, Peng K, Li Y, Li J. Association between long-term exposure to ambient air pollution and clinical outcomes among patients with heart failure: Findings from the China PEACE prospective heart failure study. Ecotoxicol Environ Saf 2021; 222: 112517.
6. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentritt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013; 165: 575–582.e3.
7. Jankowska EA, Rozentrypt P, Wiktowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JVI, Anker SD, Ponikowski P. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872–1880.
8. Rocha BM, Cunha GJ, Menezes Falcao LF. The burden of iron deficiency in heart failure: Therapeutic approach. J Am Coll Cardiol 2018; 71: 782–793.
9. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anaemia, exercise capacity, and survival. J Am Coll Cardiol 2011; 58: 1241–1251.
10. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bölüm M, Doletsy A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A. EFFECT-HF Investigators. Effect of ferri Carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136: 1374–1383.
11. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Folds G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103–112.
12. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic chronic heart failure and iron deficiency. Eur Heart J 2015; 36: 657–668.
13. Jankowska EA, Tkaczczyszyn M, Suchocki T, Drozd M, von Haehling S, Dobehler W, Banasiak W, Filippatos G, Anker SD, DOI: 10.1002/ehf2.14020
21. Sagita RS, Suryani LD, Siswanto BB, Nimsri N, Soerarso NH. The effects of ferrous sulfate supplementation on left ventricular intrinsic function by global longitudinal strain in systolic heart failure patient with iron deficiency anemia. Heart failure 2017 and the 4th world congress on acute heart failure. Eur J Heart Fail 2017; 19: 550.

22. Cooke A, Smith D, Booth A. Beyond PICO: The SPIDER tool for qualitative evidence synthesis. Qual Health Res 2012; 22: 1435–1443.

23. SchulzKF, Chalmers J, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408–412.

24. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Sorensen EV, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

25. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.

26. Zdravkovic SC, Nagorni SP, Cobjasic J, Mitic V, Cveticovic P, Nagorni I, Govedarovic D, Davinic I, Stanojevic D. Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompen-sated chronic heart failure. J Int Med Res 2019; 47: 3179–3189.

27. Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure. Circulation 2016; 133: 1606–1703.

28. Roemhild K, von Maltzahn F, Roncalli J, Elbaz M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: Experimental evidence and clinical implications. Eur J Heart Fail 2016; 18: 762–773.

29. Chatterjee NA, Murphy RM, Malhotra R, Dhakal BP, Baggish AL, Pappagianopoulos PP, Hough SS, Semigran MJ, Lewis GD. Prolonged mean VO2 response time in systolic heart failure: An indicator of impaired right ventricular-pulmonary vascular function. Circ Heart Fail 2013; 6: 499–507.

30. Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ, Sengelov M, Jærgensen PG, Mogelvang R, Shah AM, Jensen JS. Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: The Copenhagen City heart study. Circ Cardiovasc Imaging 2017; 10: e005521.

31. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2435–2448.

32. Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKinlay AJ, Trinder D, Andersen GJ. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002; 123: 835–844.

33. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–788.

34. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen SJ, Norgaard AM, Alberghini A, Campossini N, Castagna A, Viganò A, Santambrogio P, Kempf T, Wollert KC, Moutereau S, Lundby C, Cairo G. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 2009; 113: 6707–6715.